首页> 外文期刊>Molecular medicine. >A superagonistic monoclonal antibody for CD28 ameliorates crescentic glomerulonephritis in wistar-kyoto rats.
【24h】

A superagonistic monoclonal antibody for CD28 ameliorates crescentic glomerulonephritis in wistar-kyoto rats.

机译:CD28的超激动性单克隆抗体可改善wistar-kyoto大鼠的新月型肾小球肾炎。

获取原文
获取原文并翻译 | 示例
           

摘要

Regulatory T (Treg) cells play an important role in the resolution of crescentic glomerulonephritis, where a T helper 1 (Th1)-predominant immune response promotes crescent formation. Therefore, agents that increase Treg cells appear to be ideal for suppressing T-cell-mediated renal pathology. We hypothesized that a superagonistic monoclonal antibody for CD28 (JJ316), which has been known to preferentially expand Treg cells in vivo, could prevent nephrotoxic serum-induced nephritis in Wistar-Kyoto rats, one of the experimental models of crescentic glomerulonephritis. Administration of JJ316 attenuated crescent formation, proteinuria and glomerular accumulation of macrophages and CD8(+) T cells. These changes were accompanied by increased infiltration of Treg cells. Among glomerular macrophages, the CD163(+) subset was significantly increased after treatment, suggesting that Treg cells may modulate the phenotype of macrophages leading to resolution of glomerulonephritis. In an adoptive transfer experiment, two T-cell subsets (CD4(+)CD25(+) and CD4(+)CD25(-) T cells) purified from spleens and lymph nodes of donor rats primed with JJ316 3 d before were inoculated into nephritic recipient rats, which recapitulated the beneficial effects of in vivo administration of JJ316. Furthermore, a single injection of JJ316 administered 3 d after disease induction completely protected nephritic rats from death for 2 months. In conclusion, we demonstrated that treatment with JJ316 has a dramatic therapeutic effect on an experimental crescentic glomerulonephritis, possibly due to expansion and activation of Treg cells.
机译:调节性T(Treg)细胞在新月形肾小球肾炎的解决中起着重要作用,其中以T辅助1(Th1)为主的免疫反应促进新月形的形成。因此,增加Treg细胞的药物似乎是抑制T细胞介导的肾脏病理的理想药物。我们假设CD28的超激动性单克隆抗体(JJ316)已知可以优先体内扩增Treg细胞,可以预防Wistar-Kyoto大鼠肾毒性血清诱发的肾炎,这是新月型肾小球肾炎的实验模型之一。 JJ316的管理减弱了巨噬细胞和CD8(+)T细胞的新月形形成,蛋白尿和肾小球积聚。这些变化伴随着Treg细胞浸润的增加。在肾小球巨噬细胞中,治疗后CD163(+)亚群显着增加,表明Treg细胞可能调节巨噬细胞表型,导致肾小球肾炎消退。在过继性转移实验中,将两个J细胞从CD4(+)CD25(+)和CD4(+)CD25(-)T细胞亚群中纯化,这些亚细胞是从接种JJ316 3 d的供体大鼠的脾脏和淋巴结中纯化得到的,肾性受体大鼠,概括了体内施用JJ316的有益作用。此外,在诱发疾病后3天单次注射JJ316可以完全保护肾病大鼠2个月免于死亡。总之,我们证明了用JJ316进行的治疗对实验性新月形肾小球肾炎具有显着的治疗作用,这可能是由于Treg细胞的扩增和活化所致。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号